Annovis Bio, Inc. (ANVS)
NYSE: ANVS · Real-Time Price · USD
4.550
-0.100 (-2.15%)
At close: Dec 5, 2025, 4:00 PM EST
4.600
+0.050 (1.10%)
After-hours: Dec 5, 2025, 7:25 PM EST
Annovis Bio Employees
As of December 31, 2024, Annovis Bio had 15 total employees, including 8 full-time and 7 part-time employees. The number of employees decreased by 1 or -6.25% compared to the previous year.
Employees
15
Change (1Y)
-1
Growth (1Y)
-6.25%
Revenue / Employee
n/a
Profits / Employee
-$1,658,963
Market Cap
120.59M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
ANVS News
- 2 days ago - Annovis To Present at the 2025 Annual Meeting of the Parkinson Study Group - GlobeNewsWire
- 11 days ago - Annovis Announces Two Presentations at the CTAD 2025 Conference - GlobeNewsWire
- 17 days ago - Annovis Announces FDA Meeting to Discuss Parkinson's Disease Dementia Program; Reaffirms FDA Alignment on Pivotal Phase 3 Alzheimer's Disease Study - GlobeNewsWire
- 18 days ago - Annovis Bio Stock Jumps As New Data Shows Buntanetap Halts Cognitive Decline In Parkinson's Patients - Benzinga
- 18 days ago - Annovis Reports New Biomarker Data Linking Amyloid Co-Pathology to Accelerated Cognitive Decline in Parkinson's Patients - GlobeNewsWire
- 23 days ago - Annovis Provides Corporate Updates and Reports Third Quarter 2025 Financial Results - GlobeNewsWire
- 4 weeks ago - Annovis Achieves Significant Milestones and Sustains Strong Progress in Phase 3 Alzheimer's Program - GlobeNewsWire
- 5 weeks ago - Annovis Announces $3.4 Million Registered Direct Offering of Common Stock Priced At-the-Market under the NYSE Rules - GlobeNewsWire